Free Trial

Colleen Kusy Analyst Performance

Analyst at Robert W. Baird

Colleen Kusy is a stock analyst at Robert W. Baird in the medical sector, covering 6 publicly traded companies. Over the past year, Colleen Kusy has issued 9 stock ratings, including buy and hold recommendations. While full access to Colleen Kusy's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Colleen Kusy's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
9 Last 0 Years
Buy Recommendations
66.67% 6 Buy Ratings
Companies Covered
6 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy66.7%6 ratings
Hold33.3%3 ratings
Sell0.0%0 ratings

Out of 9 total stock ratings issued by Colleen Kusy at Robert W. Baird, the majority (66.7%) have been Buy recommendations, followed by 33.3% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
6 companies

Colleen Kusy, an analyst at Robert W. Baird, currently covers 6 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
6 companies
100.0%

Colleen Kusy of Robert W. Baird specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
5 companies
83.3%
MED - DRUGS
1 company
16.7%

Colleen Kusy's Ratings History at Robert W. Baird

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Climb Bio, Inc. stock logo
CLYM
Climb Bio
8/15/2025Initiated Coverage$1.72$9.00Outperform
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
7/18/2025Boost Price Target$20.04$50.00Outperform
Nuvalent, Inc. stock logo
NUVL
Nuvalent
6/25/2025Boost Price Target$77.29$112.00Outperform
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
6/16/2025Boost Price Target$21.91$52.00Outperform
Agenus Inc. stock logo
AGEN
Agenus
6/4/2025Boost Price Target$5.00$6.00Neutral
Agenus Inc. stock logo
AGEN
Agenus
5/13/2025Boost Price Target$3.50$4.00Neutral
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
5/8/2025Lower Price Target$17.99$47.00Outperform
Oculis Holding AG stock logo
OCS
Oculis
3/13/2025Boost Price Target$18.84$41.00Outperform
Agenus Inc. stock logo
AGEN
Agenus
3/12/2025Lower Price Target$2.05$3.00Neutral